Skip to main content
Download PDF

Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis

BMC Infectious Diseases volume 21, Article number: 340 (2021) Cite this article

The Original Article was published on 26 February 2021

Correction to: BMC Infect Dis 21, 222 (2021)

https://doi.org/10.1186/s12879-021-05850-0

Following publication of the original article [1], the authors identified errors in Figs. 3a, b and 4. The correct figures are given below.

Fig. 3
figure 1

Efficacy Results. a VS Risk Difference (RE model). b CD4 difference (FE model)

Full size image
Fig. 4
figure 2

Odds of all-cause discontinuation (FE model)

Full size image

The original article has been corrected.

Reference

  1. Nickel K, et al. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC Infect Dis. 2021;21:222. https://doi.org/10.1186/s12879-021-05850-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmerit International, Berlin, Germany

    Katharina Nickel

  2. Pharmerit International, Rotterdam, Netherlands

    Nicholas J. A. Halfpenny

  3. Pharmerit International, Bethesda, MD, USA

    Sonya J. Snedecor

  4. ViiV Healthcare, GSK House, 980 Great West Rd, Brentford, Middlesex, TW8 9GS, UK

    Yogesh Suresh Punekar

Authors
  1. Katharina Nickel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas J. A. Halfpenny
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sonya J. Snedecor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yogesh Suresh Punekar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yogesh Suresh Punekar.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nickel, K., Halfpenny, N.J.A., Snedecor, S.J. et al. Correction to: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis. BMC Infect Dis 21, 340 (2021). https://doi.org/10.1186/s12879-021-06016-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12879-021-06016-8

BMC Infectious Diseases

ISSN: 1471-2334

Contact us